Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions

Cancer

Volumn 95, Issue 9, 2002, Pages 1963-1970

  Simonetti, Oriana ^a,b   Lucarini, Guendalina ^a   Brancorsini, Donatella ^a   Nita, Petronela ^a   Bernardini, Maria Luisa ^a   Biagini, Graziella ^a   Offidani, Annamaria ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

Author keywords

Immunohistochemistry; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Melanoma; Nevi; Vascular endothelial growth factor

Indexed keywords

GELATINASE A; GELATINASE B; VASCULOTROPIN;

ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CANCER STAGING; DYSPLASTIC NEVUS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; JUVENILE MELANOMA; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; SKIN BIOPSY; TUMOR CELL;

DYSPLASTIC NEVUS SYNDROME; ENDOTHELIAL GROWTH FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MELANOMA; NEOPLASM INVASIVENESS; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; SKIN; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036840543     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10888     Document Type: Article

References (56)

1. Albino AP, Reed JA, McNutt NS. Molecular biology of cutaneous malignant melanoma. In: De Vita VT Jr., Hellman S, Rosemberg SA, editors, Cancer. Principles and Practice of Oncology. New York: Lippincott-Raven, 1997:1935.
2. Hanahan D, Folkmann J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757.
4. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr., Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest. 1992;67:331-337.
5. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol. 1994;145:510-514.
6. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization: Implications for tumor progress. Am J Pathol. 1994;144:329-336.
7. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutaneous Pathol. 1998;25:2-10.
8. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptor. FASEB J. 1999;13:9-22.
9. Dvorak HF, Brown LF, Detmar M, Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
10. Ferrara N, Houk K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 1992;13:18-32.
11. Conn G, Bayne ML, Soderman DD, et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci USA. 1990;87:2628-2632.
12. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 1992;153:557-562.
13. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902-906.
14. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet. 1990;6:121-125.
15. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548-2555.
16. Stetler-Stevenson W, Liotta LA, Kleiner D. Extracellular matrix. Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
17. Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behaviour. Cancer Metast Rev. 1990;9:353-367.
18. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037-1057.
19. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CH, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67-68.
20. Curran S, Murray GI. Matrix metalloproteinases in tumor invasion and metastasis. J Pathol. 1999;189:300-308.
21. Cordell JL, Falini B, Erber WN. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem. 1984;32:219-229.
22. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Rec Progr Hormone Res. 2000;55:15-35.
23. Weistat-Slatow DL, Zabrenetzky VS, Van Houtte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis. Cancer Res. 1994;54:6504-6511.
24. Streit M, Riccardi L, Velasco P, et al. Thrombospondin 2: A potent endogenous inhibitor of tumor growth and angio-genesis. Proc Natl Acad Sci USA. 1999;96:14888-14893.
25. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493-1495.
26. Bayer-Garner IB, Hough AJ, Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: Prognostic versus diagnostic usefulness. Mod Pathol. 1999;12:770-774.
27. Salven P, Heikkla P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997;76:930-934.
28. Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis. Cancer Metast Rev. 2000;19:19-27.
29. Xiong S, Grijalva R, Zhang L, et al. Up-regulation of vascular endothelial growth factor in breast cancer by the heregulinbeta 1 activated p38 signalling pathway enhance endothelial cell migration. Cancer Res. 2001;15:1727-1732.
30. Bermont L, Lamielle F, Lorchel F, et al. Insulin up-regulates vascular endothelial growth factor and stabilizers its messengers in endometrial adenocarcinoma cells. J Clin Endocrinol Metab. 2001;86:363-368.
31. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β. Proc Natl Acad Sci USA. 2000;97:10972-10977.
32. Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Makela S, Chiappetti GM. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect. 2000;108 S5:785-790.
33. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulate endothelial growth factor expression in human glioblastoma cell pathway involving phosphatidylinositol 3′-kinase and distinct induced by hypoxia. Cancer Res. 2000;60:5879-5886.
34. Danielsen T, Rofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenograft. Int J Cancer. 1998;76:836-841.
35. Claffey KP, Abrams K, Shih SC, Brown LF, Mullen A, Keough M. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab Invest. 2001;81:61-75.
36. Redondo P, Bandres E, Solano T, Okroujnov I, Garcia-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine. 2000;12:374-378.
37. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 1995;270:25915-25919.
38. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994;9:963-969.
39. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angio-genesis and experimental metastasis. Cancer Res. 1996;56:172-181.
40. Rofstad EK, Danielsen T. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer. 1998;77:897-902.
41. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol (Heart Circ Physiol). 1996;270:H1803-H1811.
42. Graeven U, Fiedler W, Karpinski S, et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol. 1999;125:621-629.
43. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol. 1995;105:170-176.
44. Qin H, Moellinger JD, Wells A, Windsor LJ, Sun Y, Benveniste EN. Transcriptional regulation of matrix metalloproteinse-2 expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol. 1998;161:6664-6673.
45. Durko M, Navab R, Shibata HR, Brodt P. Suppression of basement membrane Type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta. 1997;1356:271-280.
46. Huijzer JC, Uhlenkott CE, Meadows GG. Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants. Lack of association with in vitro invasion. Int J Cancer. 1995;63:92-99.
47. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, De-Clerk YA. Effect of tissue inhibitor of the matrix metalloproteinase 2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 1994;54:5467-5473.
48. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Matrix-metalloproteinase 2 (72 kD Type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol. 1996;180:283-289.
49. Van den Oord JJ, Paemen L, Opdenakker G, de-Wolf-Paemen C. Expression of gelatinase B and extracellular matrix metalloproteinase inducer EMMPRIM in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997;151:665-670.
50. Walker RA, Wooley DE. Immunolocalisation studies of matrix metalloproteinases-1, -2, and -3 in human melanoma. Virchows Arch. 1999;435:574-579.
51. Schaumburg-Lever G, Lever I, Fehrenbacher B, et al. Melanocytes in nevi and melanomas synthesize basement membrane and basement membrane-like material. An immunohistochemical and electron microscopic study including immuno-electron microscopy. J Cutaneous Pathol. 2000;27:67-75.
52. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases. A review. Crit Rev Oral Biol Med. 1993;4:197-250.
53. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. Proteolytic switching: Opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B expression. Br J Cancer. 1999;80:504-512.
54. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K. Localization of messenger RNA for M 72000 and 92000 Type W collagenases in human skin cancers by in situ hybridization. Cancer Res. 1992;52:1336-1341.
55. Rao JS, Yamamoto M, Mohaman S, et al. Expression and localization of 92 kDa Type W collagenase gelatinase B (MMP-9) in human gliomas. Clin Exp Metast. 1996;14:12-18.
56. Ueda Y, Imai K, Tsuchiya H, et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol. 1996;148:611-622.